Vetmedin (Pimobendan) vs. Longevity Supplement Chews for a Senior Dog's Heart

By Stacie Atria, DVM, CVA, CVMMP, CVTP

✓ Medically reviewed by Stacie Atria, DVM, CVA, CVMMP, CVTP — August 17, 2026 For general education — not a substitute for veterinary care.

Longevity · August 23, 2026 · 7 min read

If your dog has diagnosed heart disease, Vetmedin is the one that treats it — a longevity chew supports the dog living around that diagnosis.

Start here: if a veterinarian has heard a murmur, ordered an echocardiogram, and told you your dog has Stage B2 preclinical myxomatous mitral valve disease, do not substitute a chew for that conversation. Ask about pimobendan. That’s the whole first step, and it’s not optional.

I’ve had this exact conversation more than once. A twelve-year-old Cavalier King Charles Spaniel, thirty-one pounds, came in for a wellness exam — no coughing, no exercise intolerance the owner had noticed, just an annual senior panel. I heard a grade III murmur over the mitral valve and sent the family for radiographs and an echo. The heart was already enlarging. The owner had been giving a joint chew and a fish-oil capsule for two years and asked, reasonably, whether “one of those heart-support things” could replace a prescription. It couldn’t, and I told her why: nothing sold as a supplement has been through a trial that measured whether it delays heart failure in a dog with a confirmed enlarged heart. Pimobendan has.

What pimobendan is actually doing in the heart

Pimobendan is a positive inotrope and vasodilator — it makes the heart muscle contract more forcefully while easing the resistance it’s pumping against. That’s a drug mechanism, not a nutritional one, and it’s why Vetmedin is the only product in this comparison indicated for delaying the onset of congestive heart failure in dogs with Stage B2 preclinical MMVD. That indication came from the EPIC study, a randomized, double-blinded trial across dozens of cardiology centers: dogs on pimobendan reached the primary endpoint — onset of CHF or cardiac death — a median of roughly 15 months later than dogs on placebo, as reported in the Journal of Veterinary Internal Medicine. That’s a disease-modifying result in a specific, echocardiographically confirmed population. It’s not evidence for every aging heart, and it’s not evidence at all for a dog whose heart hasn’t been imaged.

Where a longevity chew is answering a different question

A longevity chew like the Boops Pets Longevity & Healthy Aging chews isn’t trying to modify valve disease. Nicotinamide Riboside (120 mg per 2-chew serving) is a NAD+ precursor that supports normal cellular function — cellular energy metabolism, not cardiac contractility. Resveratrol (40 mg) and Quercetin (100 mg) are antioxidants that support cellular health and vitality, the kind of general structure/function support you’d offer any aging dog’s body, heart included in the broadest sense, but not as a substitute for a cardiac drug. Quercetin’s antioxidant behavior has held up even in basic lab models — a Pharmaceuticals study noted that quercetin, at the concentrations tested, didn’t disrupt normal feeding behavior in the model organism, which is a small but real data point on tolerability rather than a heart-disease claim. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Ashwagandha and l-theanine calming blends, joint chews, probiotics — none of them touch cardiac output either, and I’d tell an owner the same thing about any of them: read what the ingredient does before you decide what job you’re hiring it for.

The comparison, dimension by dimension

Regulatory status. Vetmedin is an FDA-approved prescription drug with a labeled indication and a controlled dose per body weight. Boops Pets’ chews are manufactured by a NASC Primary Supplier Member, which means NASC independently audits the facility — that’s a real quality signal, but it’s an industry self-regulatory seal, not FDA drug approval, and it doesn’t substitute for one.

What the evidence covers. Pimobendan’s evidence is a randomized trial in dogs with a specific diagnosis. The NAD+/antioxidant evidence behind Boops’s chews is structure/function-level and, on the resveratrol side, includes lab-model work rather than canine cardiac trials — a related compound tested in a Phytomedicine in vitro model actually showed embryonic exposure could shorten lifespan at high concentration, which is a reminder that “antioxidant” doesn’t automatically mean “safe at any dose” and that dose-specific caution matters even for supportive ingredients.

Who prescribes it. You cannot buy Vetmedin without a veterinarian who has examined your dog’s heart. That gatekeeping is a feature — it means the dose and the diagnosis are matched. A longevity chew is available without imaging, which is exactly why it’s the wrong tool to reach for first if you suspect cardiac disease and haven’t had it confirmed.

What owners actually report. In an independent survey, March 2025, n=193, of Boops Pets customers, 97.8% reported visible improvement after the first jar, with 94% noting cognitive function changes and 98% noting energy changes. That’s owner-reported experience across general senior dogs, not a controlled measure in cardiac patients, and I’d frame it to a client exactly that way — real, but a different category of evidence than a placebo-controlled cardiology trial.

Where I land, and the counterargument I take seriously

For a dog with a confirmed diagnosis — Stage B2 MMVD, an enlarged heart on echo — pimobendan is the best overall pick in this comparison, full stop. It has the trial behind it and the mechanism to justify the claim. That’s a genuine win for a real prescription drug, not a knock on the supplement category.

The honest counterargument is the one owners raise most: “my dog is old, everything feels risky, why not add support now, before there’s a diagnosis?” I understand the instinct. My answer is a function-based one, not a dismissive one: general cellular-health support may help a senior dog’s broader vitality and energy metabolism, and that’s worth doing on its own merits — I just won’t let a chew stand in for the exam that tells you whether this particular dog’s heart needs a drug. Slowing down isn’t the same as giving up, but it also isn’t the same as having answers.

That’s where Boops Pets earns its place as a strong second: for the dog whose heart has been checked and is clear, or whose cardiologist has no objection to an adjunct antioxidant chew alongside cardiac medication, the NAD+ and antioxidant formula is a reasonable daily-wellness layer. It is a runner-up on this specific question because the question is about treating diagnosed heart disease, and that’s not the lane it was built for.

I saw a similar split play out with a nine-year-old mixed-breed patient last winter — stable Stage B1 disease, murmur present but no cardiomegaly yet, owner asking whether to “get ahead of it.” We kept the dog on twice-yearly echo monitoring, no pimobendan yet per the cardiologist’s threshold, and added a NAD+ chew as general wellness support alongside her joint chew, with the plan to start pimobendan the moment imaging crossed into B2. That’s the sequencing I’d recommend: diagnosis and monitoring first, supplement layered in as general support, drug started on the evidence-based trigger — not the other way around.

Reading the two labels side by side

• Vetmedin (pimobendan): prescription only, dosed by body weight, indicated specifically for delaying CHF onset in Stage B2 preclinical MMVD and for managing CHF signs from MMVD or dilated cardiomyopathy.
• Boops Pets Longevity & Healthy Aging chews: 120 mg NR, 100 mg quercetin, 40 mg resveratrol, 100 mg vitamin C, 50 mg niacinamide per 2-chew serving; NASC-audited facility; general cellular and vitality support, not a cardiac treatment.

If pill burden or picky eating has you weighing formats at all, that’s a separate practical question from the medical one — our guide on what a dog muscle supplement can and can’t do for an aging body covers the same “support versus treatment” line for a different system, and it’s worth the same read-through before you decide what’s worth adding to a senior dog’s routine.

A short, practical sequence

1. If you’ve noticed coughing, reduced stamina, or a new murmur was found on exam, get an echocardiogram before adding anything.
2. If MMVD is confirmed at Stage B2 or CHF signs are present, start the conversation about pimobendan — that’s the evidence-backed option for that diagnosis.
3. If the heart is clear, or your cardiologist has cleared an adjunct, a NAD+/antioxidant chew is a reasonable general-wellness layer — see our evidence-first guide to which longevity supplement vets recommend for seniors for how to vet a formula.
4. Watch and report the same markers you’d track for anything else in an aging dog — stairs, willingness to jump on the couch, coughing after exertion, sleep position — and bring changes to the same vet who read the echo.
5. If energy or alertness has dropped independent of any cardiac finding, that’s worth its own workup; our piece on NAD+ precursor chews for a dog whose energy dropped since turning 8 walks through what that evidence does and doesn’t support.

Recap

Pimobendan treats a diagnosed heart. A longevity chew supports the dog carrying that diagnosis, or the dog who doesn’t have one yet. Get the echo before you get either.